Key result
Endothelin-1 produced vasoconstriction in small intramyometrial arteries that was approximately three times as powerful and 70-fold as potent as noradrenalin.
Why the study?
Does endothelin-1 produce stronger vasoconstriction than noradrenalin in small intramyometrial arteries of term pregnant women?
Does endothelin-1 produce stronger vasoconstriction than noradrenalin in small intramyometrial arteries of term pregnant women?
Endothelin-1 is a highly potent vasoconstrictor in human intramyometrial arteries, suggesting a role in regulating utero-placental blood flow.
Answers are grounded in this paper and cite their sources.
Suggests endothelin-1 regulates utero-placental flow; animal data leave open relevance to human pregnancy.
This study was performed to evaluate the in vitro effects of a new polypeptide, endothelin-1 (ET-1) on small intramyometrial vessels in comparison with the action of noradrenalin (NA). In connection with cesarean section, myometrial biopsies were obtained and small arteries (100-500 microns in diameter) were excised. Cylindrical segments of these vessels were used for registration of contractile activity after administration of ET-1 and NA. ET produced vasoconstriction and was approximately three times as powerful and 70-fold as potent as NA. It is suggested that ET may be involved in the regulation of human utero-placental blood flow.
No takes yet. Share an insight, caveat, or question.
Lindblom et al. (1991) studied Term pregnancy. Endothelin-1 (ET-1) vs. Noradrenalin (NA) was evaluated on Contractile activity (vasoconstriction) (3 times as powerful and 70-fold as potent as NA). Endothelin-1 produced vasoconstriction in small intramyometrial arteries that was approximately three times as powerful and 70-fold as potent as noradrenalin.
Synapse has enriched 10 related papers. Consider them for comparative context: